Thromb Haemost 1989; 61(01): 015-019
DOI: 10.1055/s-0038-1646519
Original Article
Schattauer GmbH Stuttgart

ARIC[*]Hemostasis Study - I. Development of a Blood Collection and Processing System Suitable for Multicenter Hemostatic Studies

A C Papp
1   The Vascular Disease Research Center, University of Texas Health Science at Houston, Houston, Texas, USA
2   The Division of Hematology/Oncology, University of Texas Health Science at Houston, Houston, Texas, USA
,
H Hatzakis
1   The Vascular Disease Research Center, University of Texas Health Science at Houston, Houston, Texas, USA
2   The Division of Hematology/Oncology, University of Texas Health Science at Houston, Houston, Texas, USA
,
A Bracey
3   The Departments of Medicine and Pathology, University of Texas Health Science at Houston, Houston, Texas, USA
,
K K Wu
1   The Vascular Disease Research Center, University of Texas Health Science at Houston, Houston, Texas, USA
2   The Division of Hematology/Oncology, University of Texas Health Science at Houston, Houston, Texas, USA
3   The Departments of Medicine and Pathology, University of Texas Health Science at Houston, Houston, Texas, USA
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 28. Juli 1988

Accepted after revision 21. Oktober 1988

Publikationsdatum:
24. Juli 2018 (online)

Summary

In order to carry out a multicenter study aimed at understanding the association of hemostatic factors with atherosclerotic vascular disorders for the Atherosclerosis Risk In Communities (ARIC) Study, we compared a blood collection and processing system developed in our laboratory with the state-of-the-art- procedures. The salient features of our system included the use of a new phlebotomy set for venipuncture, the use of Millipore filters for removing platelet residues in the plasma and the use of a mixture of anticoagulants and antiplatelet agents for inhibiting the in vitro activation of platelets, coagulation and fibrinolytic system. The results derived from systematic evaluations indicate that this newly developed system yields the lowest values of plasma ßTG, PF 4 and FPA when compared with the reported values. The technique also gave reliable values of representative hemostatic measurements such as fibrinogen, factor VII, factor VIII, von Willebrand factor, antithrombin-III, protein C, tissue- type plasminogen activator, and serum thromboxane B2. Further experiments revealed that the samples withstood temporary storage at −70° C and overnight “shipping” manipulations without significant changes in the hemostatic values. We conclude that the described blood collection and processing system may be a valuable asset for conducting multicenter cooperative clinical trials and epidemiologic studies involving blood collection by multiple field centers or clinics.

* ARIC is the acronym for Atherosclerosis Risk In Communities. It is a prospective epidemiologic study involving 4 diversified U. S. Communities Central laboratories and Coordinating Center. A major component of the ARIC study is to determine the association between hemostatic factors and atherosclerosis and its clinical sequelae. This paper is the first of a series of paper pertaining to hemostasis studies.


 
  • References

  • 1 Kaplan KL. ß-Thromboglobulin. Prog Hemostas Thromb 1980; 5: 153-178
  • 2 Lowe GD O. Laboratory evaluation of hypercoagulability. Clin Haematol 1981; 10: 407-442
  • 3 Wu KK, Hatzakis H, Papp AC. Cellular and molecular markers of thrombosis. Hematol Pathol 1987; 1: 249-260
  • 4 Atherosclerosis Risk in Communities Study Manual 9: Hemostasis determinations. Published by the National Heart Lung and Blood Institute of the National Institute of Health, Collaborative Studies Coordinating Center, University of North Carolina. Chapel Hill; NC: 28.04.1987
  • 5 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-246
  • 6 Chakrabarti RR, North WR S. et al Haemostatic function and ischemic heart disease: Principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-537
  • 7 Hall ER, O’Brien R. The reduction of potential TXB2 levels when serum is preincubated at room temperature. Prostagl Leukotriene Med 1984; 13: 279-280
  • 8 Ludlam CA, Cash JD. Studies on the liberation of ß-thromboglobulin from platelets in vitro. Br J Haematol 1976; 33: 239-247
  • 9 Ludlam CA. Evidence for the platelet specificity of ß-thromboglobulin and studies on its plasma concentration in healthy subjects. Br J Haematol 1979; 41: 271-278
  • 10 Kudryk B, Robinson D, Netre C. et al Measurement in human blood of fibrinogen/fibrin fragments containing the Bß 15-42 sequence. Thromb Res 1982; 25: 277-287
  • 11 Celia G, Zahari J, de Haas H, Kakkar VV. ß-thromboglobulin platelet production time and platelet function in vascular disease. Br J Haematol 1979; 43: 127-136
  • 12 Smitherman TC, Milam M, Woo J, Willerson J, Frenkel EP. Elevated ß-thromboglobulin in peripheral venous blood in patients with acute myocardial ischemia: direct evidence for enhanced platelet reactivity in vivo. Am J Cardiol 1981; 48: 395-402
  • 13 Stewart ME, Douglas JT, Lowe GD O, Prentice CR M, Forbes CD. Prognostic value of ß-thromboglobulin in patients with transient cerebral ischemia. Lancet 1983; 2: 479-482
  • 14 Dawes J, Smith RC, Pepper DS. The release, distribution and clearance of human ß-thromboglobulin and platelet factor 4. Thromb Res 1978; 12: 851-861
  • 15 Handin RI, McDonough M, Lesch M. Elevation of platelet factor 4 in acute myocardial infarction: measurement by radioimmunoassay. J Lab Clin Med 1978; 91: 340-349
  • 16 Chesterman CN, McGready JR, Doyle DJ, Morgan FJ. Plasma levels of platelet factor 4 measured by radioimmunoassay. Br J Haematol 1978; 40: 489-500
  • 17 Levine SP, Lindenfeld J, Ellis JB, Raymond NM, Krentz LS. Increased plasma concentrations of platelet factor 4 in coronary artery disease. Circulation 1981; 64: 626-632
  • 18 White GC, Marouf AA. Platelet factor 4 levels in patients with coronary artery disease. J Lab Clin Med 1981; 97: 369-378
  • 19 Jaffe AS, Lee RC, Perez JE, Geltman EM, Wilner GD, Sobel BE. Lack of elevation of platelet factor 4 in patients with myocardial infarction. J Am Coll Cardiol 1984; 4: 653-659
  • 20 Nossel HJ, Yudelman I, Canfield RE, Butler VP, Spanondis Jr K, Wilner GD, Qureshi GD. Measurement of fibrinopeptide A in human blood. J Clin Invest 1974; 54: 43-53
  • 21 Kockum C, Frebelius S. Rapid radioimmunoassay of human fibrinopeptide A. Removal of cross reacting fibrinogen with bentonite Thromb Res 1980; 19: 589-598
  • 22 Cronlund M, Hardin J, Burton J, Lee L, Haber E, Bloch KJ. Fibrinopeptide A in plasma of normal subjects and patients with DIC and SLE. J Clin Invest 1976; 58: 142-151
  • 23 Hofmann V, Straub PW. A radioimmunoassay technique for the rapid measurement of human fibrinopeptide A. Thromb Res 1977; 11: 171-181
  • 24 Gerrits BJ, Flier OT N, Vander Meer J. Fibrinopeptide A immunoreactivity in human plasma. Thromb Res 1974; 5: 197-212
  • 25 Levine SP, Suarez AJ, Sorenson RR. et al The importance of blood collection methods for assessment of platelet activation. Thromb Res 1981; 24: 433-437
  • 26 Rasi V. ß-thromboglobulin in plasma: false high values caused by platelet enrichment of the top layer of plasma during centrifugation. Thromb Res 1979; 15: 543-552
  • 27 De Boer AC, Butt R, Turpie AG G, Genton E. The use of evacuated collection tubes in the determination of plasma ß-thromboglobulin. Thromb Res 1980; 20: 693-695
  • 28 Kaplan KL, Broekman J, Chernoff A, Lesznik GR, Drillings M. Platelet α-granule proteins: Studies on release and subcellular localization. Blood 1979; 53: 604-618
  • 29 Bowie EJ, Thompson JH, Owen Jr CA. The stability of antihemophilic globulin and labile factor in human blood. Mayo Clin Proc 1964; 39: 144-149